Levofloxacin Pharmacokinetics/Pharmacodynamics, Dosing, Susceptibility Breakpoints, and Artificial Intelligence in the Treatment of Multidrug-resistant Tuberculosis

Autor: Scott K. Heysell, Paul G. Ambrose, Guy E. Thwaites, Pooi S Lee, Paula Bendet, Shashikant Srivastava, Tawanda Gumbo, Thearith Koeuth, Sujata M. Bhavnani, Devyani Deshpande, Jotam G. Pasipanodya, Stellah G. Mpagama
Jazyk: angličtina
Rok vydání: 2018
Předmět:
0301 basic medicine
Microbiology (medical)
Tuberculosis
medicine.drug_class
030106 microbiology
Antibiotics
Antitubercular Agents
Supplement Articles
Drug resistance
Levofloxacin
Microbial Sensitivity Tests
Tuberculous meningitis
lung
Mycobacterium tuberculosis
03 medical and health sciences
Moxifloxacin
Artificial Intelligence
Drug Resistance
Multiple
Bacterial

Tuberculosis
Multidrug-Resistant

pharmacodynamics
Medicine
Humans
Tuberculosis
Pulmonary

minimum inhibitory concentration measurement
biology
business.industry
Sputum
multidrug-resistant tuberculosis
medicine.disease
biology.organism_classification
probit trial
Infectious Diseases
tuberculosis
exposure
minimum inhibitory concentration result
tuberculous meningitis
Pharmacodynamics
Drug Therapy
Combination

Artificial intelligence
mutation
moxifloxacin
business
pharmacokinetics
pulmonary tuberculosis
Monte Carlo Method
Algorithms
medicine.drug
Popis: Background Levofloxacin is used for the treatment of multidrug-resistant tuberculosis; however the optimal dose is unknown. Methods We used the hollow fiber system model of tuberculosis (HFS-TB) to identify 0–24 hour area under the concentration-time curve (AUC0-24) to minimum inhibitory concentration (MIC) ratios associated with maximal microbial kill and suppression of acquired drug resistance (ADR) of Mycobacterium tuberculosis (Mtb). Levofloxacin-resistant isolates underwent whole-genome sequencing. Ten thousands patient Monte Carlo experiments (MCEs) were used to identify doses best able to achieve the HFS-TB–derived target exposures in cavitary tuberculosis and tuberculous meningitis. Next, we used an ensemble of artificial intelligence (AI) algorithms to identify the most important predictors of sputum conversion, ADR, and death in Tanzanian patients with pulmonary multidrug-resistant tuberculosis treated with a levofloxacin-containing regimen. We also performed probit regression to identify optimal levofloxacin doses in Vietnamese tuberculous meningitis patients. Results In the HFS-TB, the AUC0-24/MIC associated with maximal Mtb kill was 146, while that associated with suppression of resistance was 360. The most common gyrA mutations in resistant Mtb were Asp94Gly, Asp94Asn, and Asp94Tyr. The minimum dose to achieve target exposures in MCEs was 1500 mg/day. AI algorithms identified an AUC0-24/MIC of 160 as predictive of microbiologic cure, followed by levofloxacin 2-hour peak concentration and body weight. Probit regression identified an optimal dose of 25 mg/kg as associated with >90% favorable response in adults with pulmonary tuberculosis. Conclusions The levofloxacin dose of 25 mg/kg or 1500 mg/day was adequate for replacement of high-dose moxifloxacin in treatment of multidrug-resistant tuberculosis.
Databáze: OpenAIRE